Docoh
Loading...

ZEAL Zealand Pharma A/S.

News

From Benzinga Pro
Zealand Pharma Increases Its Share Capital, Citing Exercise Of Employee Warrant: 'exercise price was DKK 100,8 per share for 5,400 new shares'
10 Dec 21
News
https://www.globenewswire.com/news-release/2021/12/10/2350059/0/en/Zealand-Pharma-increases-its-share-capital-as-a-consequence-of-exercise-of-employee-warrants.html
Zealand Pharma Announces Outcome Of Phase 1B Clinical Trial With Dapiglutide; Dapiglutide Was Assessed To Be Safe And Well Tolerated Following 4 Weeks Of Dosing In Humans
22 Nov 21
Biotech, General
Zealand Pharma A/S (NASDAQ:ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, announces topline results from its Phase 1b
12 Health Care Stocks Moving In Thursday's Intraday Session
11 Nov 21
Movers
Gainers
Earnings Scheduled For November 11, 2021
11 Nov 21
Earnings, News, Pre-Market Outlook, Markets
Companies Reporting Before The Bell • NICE (NASDAQ:NICE) is likely to report quarterly earnings at $1.58 per share on revenue of $465.75 million.
Zealand Pharma and DEKA Research & Development Corp. Announce Collaboration Agreement To 'Advance Development of Infusion Pump to Be Used with Dasiglucagon for Treatment of Congenital Hyperinsulinism'; Financial Details Not Disclosed
5 Nov 21
Biotech, General
Zealand Pharma and DEKA Research & Development Corp. Announce Collaboration Agreement to Advance Development of Infusion Pump to Be Used with Dasiglucagon for
Zealand Pharma Reports First Subject Dosed In Phase 1 Trial Of Amylin Analogue ZP8396 For Treatment Of Obesity
4 Nov 21
Biotech, News, FDA, General
Zealand Pharma Announces First Subject Dosed in Phase 1 Trial of Amylin Analogue ZP8396 for the Treatment of Obesity Preclinical data have shown potent anti-obesity effects of ZP8396 both as a monotherapy and in
Zealand Pharma Announces Presentation Of Preclinical Data On Amylin Analogue And Clinical Data On Glucagon-GLP1 Dual-Agonist At The Obesity Society Annual Meeting
1 Nov 21
News, FDA, Events
Zealand Pharma A/S (NASDAQ:ZEAL) (CVR-no. 20045078,) a biotechnology company focused on the discovery, development and commercialization of innovative peptide-based medicines, today announced it will present preclinical

Press releases

From Benzinga Pro
Zealand Pharma to Participate in H.C. Wainwright BIOCONNECT 2022 Conference
3 Jan 22
News, Press Releases
Company announcement – No. 1 / 2022 Zealand Pharma to Participate in H.C. Wainwright BIOCONNECT 2022 Conference Copenhagen, DK and Boston, MA, U.S. January 3, 2022 – Zealand Pharma A/S (NASDAQ:ZEAL) (CVR-no. 20045078,)
Total number of shares and voting rights in Zealand Pharma at December 30, 2021
30 Dec 21
Press Releases
Company announcement – No. 78 / 2021 Total number of shares and voting rights in Zealand Pharma at December 30, 2021 Copenhagen, DK and Boston, MA, December 30, 2021 – Zealand Pharma A/S ("Zealand") (NASDAQ:ZEAL)
Zealand Pharma Announces Enrollment of Last Patient Needed for Interim Analysis of EASE-SBS 1 Phase 3 Trial Assessing Glepaglutide in Patients with Short Bowel Syndrome
16 Dec 21
Press Releases
Company announcement – No. 76 / 2021 Zealand Pharma Announces Enrollment of Last Patient Needed for Interim Analysis of EASE-SBS 1 Phase 3 Trial Assessing Glepaglutide in Patients with Short Bowel Syndrome Interim
Zealand Pharma Announces Seven-Year, $200 Million Financing Agreement with Oberland Capital
14 Dec 21
Press Releases
Company announcement – No. 75 / 2021 Zealand Pharma Announces Seven-Year, $200 Million Financing Agreement with Oberland Capital Agreement includes an upfront payment of $100 million in exchange for a 7-year,
Total number of shares and voting rights in Zealand Pharma at November 30, 2021
30 Nov 21
Press Releases
Company announcement – No. 72 / 2021 Total number of shares and voting rights in Zealand Pharma at November 30, 2021 Copenhagen, DK and Boston, MA, November 30, 2021 – Zealand Pharma A/S ("Zealand") (NASDAQ:ZEAL)
Zealand Pharma announces successful outcome of Phase 1b clinical trial with GLP1-GLP2 dual receptor agonist, dapiglutide
22 Nov 21
Press Releases
Company announcement – No. 70 / 2021 Zealand Pharma announces successful outcome of Phase 1b clinical trial with GLP1-GLP2 dual receptor agonist, dapiglutide Dapiglutide was assessed to be safe and well tolerated
Zealand Pharma to Participate in Jefferies London Healthcare Conference
12 Nov 21
News, Press Releases
Company announcement – No. 68 / 2021 Zealand Pharma to Participate in Jefferies London Healthcare Conference Copenhagen, DK and Boston, MA, U.S. November 12, 2021 – Zealand Pharma A/S (NASDAQ:ZEAL) (CVR-no.
Zealand Pharma and DEKA Research & Development Corp. Announce Collaboration Agreement to Advance Development of Infusion Pump to Be Used with Dasiglucagon for Treatment of Congenital Hyperinsulinism (CHI)
5 Nov 21
Press Releases
Company announcement – No. 66/ 2021 Zealand Pharma and DEKA Research & Development Corp. Announce Collaboration Agreement to Advance Development of Infusion Pump to Be Used with Dasiglucagon for Treatment of
Zealand Pharma Hosts Conference Call on November 11 at 4 pm CET (10 am ET) to Present Third Quarter Results for 2021
4 Nov 21
News, Press Releases
Company announcement – No. 64 / 2021 Zealand Pharma Hosts Conference Call on November 11 at 4 pm CET (10 am ET) to Present Third Quarter Results for 2021 Copenhagen, DK and Boston, MA, U.S. November 4, 2021
Zealand Pharma Announces Presentation of Preclinical Data on Amylin Analogue, ZP8396, and Clinical Data on Glucagon-GLP1 Dual-Agonist, BI 456906, at The Obesity Society Annual Meeting
1 Nov 21
Press Releases
Company announcement – No. 63 / 2021 Zealand Pharma Announces Presentation of Preclinical Data on Amylin Analogue, ZP8396, and Clinical Data on Glucagon-GLP1 Dual-Agonist, BI 456906, at The Obesity Society Annual